TrialThe oncologist2011

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

Eric Assenat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.